Ⅲ章 資料
胃癌治療を理解・実践する上で有用と思われる文献を英文論文を中心に集め，各分野ごとに出版年順にリストした（1）2）…）。ガイドライン本文の記述と直接関係するものは，本文中に文献番号（［1］［2］…）を記した。
| 1） | Bonenkamp JJ, Hermans J, Sasako M, et al：Extended lymph-node dissection for gastric cancer. N Engl J Med 1999；340：908-14. |
|---|---|
| 2） | Cuschieri A, Weeden S, Fielding J, et al：Patient survival after D1 and D2 resections for gastric cancer：long-term results of the MRC randomized surgical trial. Br J Cancer 1999；79：1522-30. |
| 3） | Wu CW, Hsiung CA, Lo SS, et al：Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004；91：283-87. |
| 4） | Degiuli M, Sasako M, Calgaro M, et al：Morbidity and mortality after D1 and D2 gastrectomy for cancer：interim analysis of the Italian gastric cancer study group（IGCSG）randomised surgical trial. EJSO 2004；30：303-8. |
| 5） | Sano T, Sasako M, Yamamoto S, et al：Gastric cancer Surgery：Morbidity and mortality results from a prospective randomized controlled trial compariwng D2 and extended para-aortic lymphadenectomy―Japan clinical oncology group study 9501. J Clin Oncol 2004；22：2767-73. |
| 6） | Kodera Y, Sasako M, Yamamoto S, et al：Identification of risk factors for the development of complications following extended and surperextended lymphadenectomies for gastric cancer. Br J Surg 2005；92：1103-09. |
| 7） | Sasako M, Sano T, Yamamoto S, et al：Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia：a randomised controlled trial. Lancet Oncol 2006；7：644-51. |
| 8） | Marrelli D, Pedrazzani C, Neri A, et al：Complications after extended（D2）and superextended（D3）lymphadenectomy for gastric cancer：Analysis of potential risk factors. Ann Surg Oncol 2007；14：25-33. |
| 9） | Yonemura Y, Wu CC, Fukushima N, et al：Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008；13：132-37. |
| 10） | Sasako M, Sano T, Yamamoto S, et al：D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Eng J Med 2008；359：453-62. |
| 11） | Tokunaga M, Ohyama S, Hiki N, et al：Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenum invasion：is the posterior pancreatic head lymph node dissection beneficial? Ann Surg Oncol 2009；16：1241-46. |
| 12） | Songun I, Putter H, Kranenbarg EM, et al：Surgical treatment of gastric cancer：15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010；11：439-49. |
| 13） | Tanizawa Y, Terashima M：Lymph node dissection in the resection of gastric cancer：review of existing evidence. Gastric Cancer 2010；13：137-48. |
| 14） | Lips DJ, Schutte HW, van der Linden RL, et al：Sentinel lymph node biopsy to direct treatment in gastric cancer. A systematic review of the literature. Eur J Surg Oncol 2011；37：655-61. |
| 15） | Yamashita H, Katai H, Morita S, et al：Optimal extent of lymph node dissection for Siewert type Ⅱ esophagogastric junction carcinoma. Ann Surg 2011；254：274-80. |
| 16） | Seevaratnam R, Bocicariu A, Cardoso R, et al：How many lymph nodes should be assessed in patients with gastric cancer? A systematic review. Gastric Cancer 2012；15：S70-88. |
| 17） | Eom BW, Joo J, Kim YW, et al：Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer? Ann Surg Oncol 2013；20：2669-75. |
| 18） | Lee HH, Yoo HM, Song KY, et al：Risk of limited lymph node dissection in patients with clinically early gastric cancer：indications of extended lymph node dissection for early gastric cancer. Ann Surg Oncol 2013；20：3534-40. |
| 19） | Asoglu O, Matlim T, Kurt A, et al：Guidelines for extended lymphadenectomy in gastric cancer：a prospective comparative study. Ann Surg Oncol 2013；20：218-25. |
| 20） | Kitagawa Y, Takeuchi H, Takagi Y, et al：Sentinel node mapping for gastric cancer：a prospective multicenter trial in Japan. J Clin Oncol 2013；31：3704-10. |
| 21） | Maehara Y, Moriguchi S, Yoshida M, et al：Splenectomy does not correlate with length of survival in patients undergoing curative total gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 1991；67：3006-9. |
|---|---|
| 22） | Maruyama K, Sasako M, Kinoshita T, et al：Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995；19：532-6. |
| 23） | Otsuji E, Yamaguchi T, Sawai K, et al：Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma. Br J Cancer 1999；79：1789-93. |
| 24） | Sano T, Yamamoto S, Sasako M：Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma：Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol 2002；32：363-4. |
| 25） | Csendes A, Burdiles P, Rojas J, et al：A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002；131：401-7. |
| 26） | Yu W, Choi GS, Chung HY：Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006；93：559-63. |
| 27） | Cheong O, Kim BS, Yook JH, et al：Modified radical lymphadenectomy without splenectomy in patients with proximal gastric cancer：comparison with standard D2 lymphadenectomy for distal gastric cancer. J Surg Oncol 2008；98：500-4. |
| 28） | Zhu GL, Sun Z, Wang ZN, et al：Splenic hilar lymph node metastasis independently predicts poor survival for patients with gastric cancers in the upper and/or the middle third of the stomach. J Surg Oncol 2012；105：786-92. |
| 29） | Brar SS, Seevaratnam R, Cardoso R, et al：A systematic review of spleen and pancreas preservation in extended lymphadenectomy for gastric cancer. Gastric Cancer 2012；15 Suppl 1：S89-99. |
| 30） | Katai H, Sano T, Fukagawa T, et al：Prospective study of proximal gastrectomy for early gastric cancer in the upper third of the stomach. Br J Surg 2003；90：850-3. |
|---|---|
| 31） | Shibata C, Shiiba KI, Funayama Y, et al：Outcomes after pylorus-preserving gastrectomy for early gastric cancer：a prospective multicenter trial. World J Surg 2004；28：857-61. |
| 32） | Kitagawa Y, Kitano S, Kubota T, et al：Minimally invasive surgery for gastric cancer-toward a confluence of two major streams：a review. Gastric Cancer 2005；8：103-10. |
| 33） | Ohdaira H, Nimura H, Mitsumori N, et al：Validity of modified gastrectomy combined with sentinel node navigation surgery for early gastric cancer. Gastric Cancer 2007；10：117-22. |
| 34） | Park do J, Lee HJ, Jung HC, et al：Clinical outcome of pylorus-preserving gastrectomy in gastric cancer in comparison with conventional distal gastrectomy with Billroth I anastomosis. World J Surg 2008；32：1029-36. |
| 35） | Morita S, Katai H, Saka M, et al：Outcome of pylorus-preserving gastrectomy for early gastric cancer. Br J Cancer 2008；95：1131-5. |
| 36） | Ishikawa S, Shimada S, Miyanari N, et al：Pattern of lymph node involvement in proximal gastric cancer. World J Surg 2009；33：1687-92. |
| 37） | Hiki N, Sano T, Fukunaga T, Ohyama S, et al：Survival benefit of pylorus-preserving gastrectomy in early gastric cancer. J Am Coll Surg 2009；209：297-301. |
| 38） | Mine S, Sano T, Tsutsumi K, et al：Large-scale investigation into dumping syndrome after gastrectomy for gastric cancer. J Am Coll Surg 2010；211：628-36. |
| 39） | Morita S, Sasako M, Saka M, et al：Correlation between the length of the pyloric cuff and postoperative evaluation after pylorus-preserving gastrectomy. Gastric Cancer 2010；13：109-16. |
| 40） | Jiang X, Hiki N, Nunobe S, et al：Postoperative outcomes and complications after laparoscopy-assisted pylorus-preserving gastrectomy for early gastric cancer. Ann Surg 2011；253：928-33. |
| 41） | Koeda K, Nishizuka S, Wakabayashi G：Minimally invasive surgery for gastric cancer：the future standard of care. World J Surg 2011；35：1469-77. |
| 42） | Hayami M, Seshimo A, Miyake K, et al：Effects of emptying function of remaining stomach on QOL in postgastrectomy patients. World J Surg 2012；36：373-8. |
| 43） | Tomikawa M, Korenaga D, Akahoshi T, et al：Quality of life after laparoscopy-assisted pylorus-preserving gastrectomy：an evaluation using a questionnaire mailed to the patients. Surg Today 2012；42：625-32. |
| 44） | Karanicolas PJ, Graham D, Gonen M, et al：Quality of life after gastrectomy for adenocarcinoma：a prospective cohort study. Ann Surg 2013；257：1039-46. |
| 45） | Kinoshita T, Gotohda N, Kato Y, et al：Laparoscopic proximal gastrectomy with jejunal interposition for gastric cancer in the proximal third of the stomach：a retrospective comparison with open surgery. Surg Endosc 2013；27：146-53. |
| 46） | Nozaki I, Hato S, Kobatake T, et al：Long-term outcome after proximal gastrectomy with jejunal interposition for gastric cancer compared with total gastrectomy. World J Surg 2013；37：558-64. |
| 47） | Furukawa H, Hiratsuka M, Iwanaga T, et al：Extended surgery―left upper abdominal exenteration plus Appleby’s method―for type 4 gastric carcinoma. Ann Surg Oncol 1997；4：209-14. |
|---|---|
| 48） | Nomura E, Niki M, Fujii K, et al：Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer. Gastric Cancer 2001；4：75-82. |
| 49） | Ambiru S, Miyazaki M, Ito H, et al：Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001；181：279-83. |
| 50） | Okano K, Maeba T, Ishimura K, et al：Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002；235：86-91. |
| 51） | Shirabe K, Shimada M, Matsumata T, et al：Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection：a multi-institutional study of the indications for resection. Hepatogastroenterol 2003；50：1560-3. |
| 52） | Saka M, Mudan SS, Katai H, et al：Pancreaticoduodenectomy for advanced gastric cancer. Gastric Cancer 2005；8：1-5. |
| 53） | Sakamoto Y, Sano T, Shimada K, et al：Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007；95：534-9. |
| 54） | Nunobe S, Hiki N, Ohyama S, et al：Survival benefits of pancreatoduodenectomy for gastric cancer：relationship to the number of lymph node metastases. Langenbecks Arch Surg 2008；393：157-62. |
| 55） | Tiberio GA, Coniglio A, Marchet A, et al：Metachronous hepatic metastases from gastric carcinoma：A multicentric survey. EJSO 2009；35：486-91. |
| 56） | Dittmar Y, Altendorf-Hofmann A, Rauchfuss F, et al：Resection of liver metastases is beneficial in patients with gastric cancer：report on 15 cases and review of literature. Gastric Cancer 2012；15：131-6. |
| 57） | Romano F, Garancini M, Uggeri F, et al：Surgical treatment of liver metastases of gastric cancer：state of the art. World J Surg Oncol 2012；10：157. |
| 58） | Schildberg CW, Croner R, Merkel S, et al：Outcome of operative therapy of hepatic metastatic stomach carcinoma：a retrospective analysis. World J Surg 2012；36：872-8. |
| 59） | Takemura N, Saiura A, Koga R, et al：Long-term outcomes after surgical resection for gastric cancer liver metastasis：an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg 2012；397：951-7. |
| 60） | Chen L, Song MQ, Lin HZ, et al：Chemotherapy and resection for gastric cancer with synchronous liver metastases. World J Gastroenterol 2013；19：2097-103. |
| 61） | Kaminishi M, Yamaguchi H, Shimizu N, et al：Stomach-partitioning gastrojejunostomy for unresectable gastric carcinoma. Arch Surg 1997；132：184-7. |
|---|---|
| 62） | Hartgrink HH, Putter H, Klein Kranenbarg E, et al：Value of palliative resection in gastric cancer. Br J Surg 2002；89：1438-43. |
| 63） | Sarela AI, Yelluri S：Gastric adenocarcinoma with distant metastasis. Arch Surg 2007；142：143-9. |
| 64） | Fujitani K, Yang HK, Kurokawa Y, et al：Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor：Japan Clinical Oncology Group study JCOG 0705 and Korea Gastric Cancer Association study KGCA01. Jpn J Clin Oncol 2008；38：504-6. |
| 65） | Saito H, Yamada Y, Tsujitani S, et al：Clinicopathologic characteristics of gastric cancer patients who underwent noncurative gastrectomy with long-term survival. Langenbecks Arch Surg 2009；394：99-103. |
| 66） | Huang KH, Wu CW, Fang WL, et al：Palliative resection in noncurative gastric cancer patients. World J Surg 2010；34：1015-21. |
| 67） | Chang YR, Han DS, Kong SH, et al：The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol 2012；19：1231-9. |
| 68） | Mahar AL, Coburn NG, Singh S, et al：A systematic review of surgery for non-curative gastric cancer. Gastric Cancer 2012；15 Suppl 1：S125-37. |
| 69） | Keränen I, Kylänpää L, Udd M, et al：Gastric outlet obstruction in gastric cancer：a comparison of three palliative methods. J Surg Oncol 2013；108：537-41. |
| 70） | Mariette C, Bruyere E, Messager M, et al：Palliative resection for advanced gastric and junctional adenocarcinoma：which patients will benefit from surgery? Ann Surg Oncol 2013；20：1240-9. |
| 71） | Sun J, Song Y, Wang Z, et al：Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer：a systematic review and meta-analysis. BMC Cancer 2013；13：577. |
| 72） | Takeno A, Takiguchi S, Fujita J, et al：Clinical outcome and indications for palliative gastrojejunostomy in unresectable advanced gastric cancer：multi-institutional retrospective analysis. Ann Surg Oncol 2013；20：3527-33. |
| 73） | Kitano S, Iso Y, Moriyama M, et al：Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc 1994；4：146-8. |
|---|---|
| 74） | Huscher CG, Mingoli A, Sgarzini G, et al：Laparoscopic versus open subtotal gastrectomy for distal gastric cancer. Ann Surg 2005；241：232-7. |
| 75） | Kitano S, Shiraishi N, Uyama I, et al：A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg 2007；245：68-72. |
| 76） | Yasuda K, Shiraishi N, Etoh T, et al：Long-term quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc 2007；21：2150-3. |
| 77） | Cho GS, Kim W, Kim HH, et al：Multicentre study of the safety of laparoscopic subtotal gastrectomy for gastric cancer in the elderly. Br J Surg 2009；96：1437-42. |
| 78） | Song J, Lee HJ, Cho GS, et al：Recurrence following laparoscopy-assisted gastrectomy for gastric cancer：a multicenter retrospective analysis of 1,417 patients. Ann Surg Oncol 2010；17：1777-86. |
| 79） | Kim HH, Hyung WJ, Cho GS, et al：Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer：an interim report--a phase Ⅲ multicenter, prospective, randomized Trial（KLASS Trial）. Ann Surg 2010；251：417-20. |
| 80） | Katai H, Sasako M, Fukuda H, et al：Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage Ⅰ gastric cancer：a multicenter phase Ⅱ trial（JCOG 0703）. Gastric Cancer 2010；13：238-44. |
| 81） | Park do J, Han SU, Hyung WJ, et al：Long-term outcomes after laparoscopy-assisted gastrectomy for advanced gastric cancer：a large-scale multicenter retrospective study. Surg Endosc 2012；26：1548-53. |
| 82） | Nakamura K, Katai H, Mizusawa J, et al：A phase Ⅲ study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage ⅠA/ⅠB gastric Cancer（JCOG0912）. Jpn J Clin Oncol 2013；43：324-7. |
| 83） | Suh YS, Han DS, Kong SH, et al：Laparoscopy-assisted pylorus-preserving gastrectomy is better than laparoscopy-assisted distal gastrectomy for middle-third early gastric cancer. Ann Surg 2014；259：485-93. |
| 84） | Takiguchi S, Fujiwara Y, Yamasaki M, et al：Laparoscopy-assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study. World J Surg 2013；37：2379-86. |
| 85） | Yu J, Hu J, Huang C, et al：The impact of age and comorbidity on postoperative complications in patients with advanced gastric cancer after laparoscopic D2 gastrectomy：results from the Chinese laparoscropic gastrointestinal surgery study（CLASS）group. Eur J Surg Oncol 2013；39：1144-9. |
| 86） | Imamura H, Kurokawa Y, Kawada J, et al：Influence of bursectomy on operative morbidity and mortality after radical gastrectomy for gastric cancer：results of a randomized controlled trial. World J Surg 2011；35：625-30. |
|---|---|
| 87） | Fujita J, Kurokawa Y, Sugimoto T, et al：Survival benefit of bursectomy in patients with resectable gastric cancer：interim analysis results of a randomized controlled trial. Gastric Cancer 2012；15：42-8. |
| 88） | Eom BW, Joo J, Kim YW, et al：Role of bursectomy for advanced gastric cancer：result of a case-control study from a large volume hospital. Eur J Surg Oncol 2013；39：1407-14. |
| 89） | Yao K, Anagnostopoulos GK, Ragunath K：Magnifying endoscopy for diagnosing and delineating early gastric cancer. Endoscopy 2009；41：462-8. |
|---|---|
| 90） | Ezoe Y, Muto M, Horimatsu T, et al：Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions：a prospective study. Gastrointest Endosc 2010；71：477-84. |
| 91） | Gotoda T, Yanagisawa A, Sasako M, et al：Incidence of lymph node metastasis from early gastric cancer：estimation with a large number of cases at two large centers, Gastric Cancer 2000；3：219-25. |
| 92） | Hanaoka N, Tanabe S, Mikami T, et al：Mixed-histologic-type submucosal invasive gastric cancer as a risk factor for lymph node metastasis：feasibility of endoscopic submucosal dissection. Endoscopy 2009；41：427-32. |
| 93） | Hirasawa T, Gotoda T, Miyata S, et al：Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer. 2009；12：148-52. |
| 94） | Kim JH, Lee YC, Kim H, et al：Addictive lymph node dissection may be necessary in minute submucosal cancer of the stomach after endoscopic resection. Ann Surg Oncol 2012；19：779-85. |
| 95） | Lee JI, Kim JH, Kim JH, et al：Indication for endoscopic treatment of ulcerative early gastric cancer according to depth of ulcer and morphological change. J Gastroenterol Hepatol 2012；27：1718-25. |
| 96） | 滝沢耕平，川田登，田中雅樹，他：組織混在パターン別粘膜内胃癌の臨床病理学的特徴 早期胃癌外科切除例からの検討および多施設調査結果．胃と腸2013；48：1567-79． |
| 97） | Hirao M, Masuda K, Asanuma T, et al：Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline-epinephrine. Gastrointest Endosc 1988；34：264-9. |
|---|---|
| 98） | Tada M, Murakami A, Karita M, et al：Endoscopic resection of early gastric cancer. Endoscopy 1993；25：445-50. |
| 99） | Inoue H, Takeshita K, Hori H, et al：Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions. Gastrointest Endosc 1993；39：58-62. |
| 100） | 小野裕之，後藤田卓志，近藤仁，他：ITナイフを用いたEMR―適応拡大の工夫―．消化器内視鏡1999；11：675． |
| 101） | Oyama T, Kikuchi Y：Aggressive endoscopic mucosal resection in the upper GI tract-hook knife EMR method. Minim Invasive Ther Allied Technol 2002；11：291-5. |
| 102） | Ono H, Hasuike N, Inui T, et al：Usefulness of a novel electrosurgical knife, the insulation-tipped diathermic knife-2, for endoscopic submucosal dissection of early gastric cancer. Gastric Cancer 2008；11：47-52. |
| 103） | Mori H, Rafiq K, Kobara H, et al：Local steroid injection into the artificial ulcer created by endoscopic submucosal dissection for gastric cancer：prevention of gastric deformity. Endoscopy 2012；44：641-8. |
| 104） | Sasaki T, Tanabe S, Azuma M, et al：Propofol sedation with bispectral index monitoring is useful for endoscopic submucosal dissection：a randomized prospective phase Ⅱ clinical trial. Endoscopy 2012；44：584-9. |
| 105） | Maeda Y, Hirasawa D, Fujita N, et al：A prospective, randomized, double-blind, controlled trial on the efficacy of carbon dioxide insufflation in gastric endoscopic submucosal dissection. Endoscopy 2013；45：335-41. |
| 106） | Ono H, Kondo H, Gotoda T, et al：Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001；48：225-9. |
|---|---|
| 107） | Coda S, Oda I, Gotoda T, et al：Risk factors for cardiac and pyloric stenosis after endoscopic submucosal dissection, and efficacy of endoscopic balloon dilation treatment. Endoscopy 2009；41：421-6. |
| 108） | 草野 央，後藤田卓志，岩崎 基，他：早期胃癌に対する内視鏡的切除後の長期予後．胃と腸2008；43：74-80． |
| 109） | Fukase K, Kato M, Kikuchi S, et al：Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer：an open-label, randomised controlled trial. Lancet 2008；372：392-7. |
| 110） | Abe N, Gotoda T, Hirasawa T, et al：Multicenter study of the long-term outcomes of endoscopic submucosal dissection for early gastric cancer in patients 80 years of age or older. Gastric Cancer 2012；15：70-5. |
| 111） | Toyokawa T, Inaba T, Omote S, et al：Risk factors for perforation and delayed bleeding associated with endoscopic submucosal dissection for early gastric neoplasms：analysis of 1123 lesions. J Gastroenterol Hepatol 2012；27：907-12. |
| 112） | Abe S, Oda I, Suzuki H, et al：Short- and long-term outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. Endoscopy 2013；45：703-7. |
| 113） | Kato M, Nishida T, Yamamoto K, et al：Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer：a multicentre retrospective cohort study by Osaka University ESD study group. Gut 2013；62：1425-32. |
| 114） | Kim M, Jeon SW, Cho KB, et al：Predictive risk factors of perforation in gastric endoscopic submucosal dissection for early gastric cancer：a large, multicenter study. Surg Endosc 2013；27：1372-8. |
| 115） | Yamada M, Oda I, Nonaka S, et al：Long-term outcome of endoscopic resection of superficial adenocarcinoma of the esophagogastric junction. Endoscopy 2013；45：992-6. |
| 116） | Pyrhönen S, Kuitunen T, Nyandoto P, et al：Randomized comparison of fluorouracil, epidoxorubicin and methotrexate（FEMTX）plus supportive care with best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995；71：587-91. |
|---|---|
| 117） | Vanhoefer U, Rougier P, Wilke H, et al：Final results of a randomized phase Ⅲ trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus infusional fluorouracil and cisplatin in advanced gastric cancer：a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 2000；18：2648-57. |
| 118） | Ohtsu A, Shimada Y, Shirao K, et al：Randomized phase Ⅲ trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with advanced gastric cancer：JCOG study 9205. J Clin Oncol 2003；21：54-9. |
| 119） | Cutsem EV, Moiseyenko VM, Tjulandin S, et al：Phase Ⅲ study of docetaxel with cisplatin and 5-fluorouracil as first-line therapy for advanced gastric cancer：a report of the V325 study group. J Clin Oncol 2006；24：4991-7. |
| 120） | Cunningham D, Starling N, Rao S, et al：Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008；358：36-46. |
| 121） | Koizumi W, Narahara H, Hara T, et al：Randomized phase Ⅲ study of S-1 alone versus S-1＋cisplatin in the treatment for advanced gastric cancer（The SPIRITS trial）SPIRITS：S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. Lancet Oncol 2008；9：215-21. |
| 122） | Imamura H, Iishi H, Tsuburaya A, et al：Randomized phase Ⅲ study of irinotecan plus S-1（IRIS）versus S-1 alone as first-line treatment for advanced gastric cancer（GC0301/TOP-002）. 2008 Gastrointestinal Cancer Symposium. |
| 123） | Boku N, Yamamoto S, Shirao K, et al：Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer：a randomized phase3 study. Lancet Oncol 2009；10：1063-9. |
| 124） | Shirao K, Boku N, Yamada Y, et al：Randomized phase Ⅲ study of 5-fluorouracil continuous infusion（5-FUci）versus methotrexate and 5-FU sequential（MF）in gastric cancer with peritoneal metastasis：JCOG 0106. Proc Am Soci Clin Oncol 2009；27：#4545. |
| 125） | Ajani JA, Rodriguez W, Bodoky G, et al：Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study：The FLAGS trial. J Clin Oncol 2010；28：1547-53. |
| 126） | Bang YJ, Van Cutsem E, Feyereislova A, et al：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3, open-label, randomised controlled trial. Lancet 2010；376：687-97. |
| 127） | Kang Y, Ohtsu A, Cutsem EV, et al：AVAGAST：A randomized, double-blind, placebo-controlled, phase Ⅲ study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer. Proc Am Soci Clin Oncol 2010；28：LBA4007. |
| 128） | Thuss-Patience PC, Kretzschmar A, Bichev D, et al：Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase Ⅲ study of the Arbeitsgemeinschaft Internistische Onkologie（AIO）. Eur J Cancer 2011；47：2306-14. |
| 129） | Choi YH, Oh SC, Kim JS, et al：A phase Ⅱ study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment：a Korean Cancer Study Group Protocol ST06-02. Cancer Chemother Pharmacol 2012；70：665-72. |
| 130） | Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer：A randomized phase Ⅲ trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012；30：1513-8. |
| 131） | Imano M, Yasuda A, Itoh T, et al：Phase Ⅱ study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg 2012；16：2190-6. |
| 132） | Ajani JA, Buyse M, Lichinitser M, et al：Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma：Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer 2013；49：3616-24. |
| 133） | Fushida S, Kinoshita J, Kaji M, et al：Phase Ⅰ/Ⅱ study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 2013；71：1265-72. |
| 134） | Hironaka S, Ueda S, Yasui H, et al：Randomized, open-label, phase Ⅲ study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum：WJOG 4007 trial. J Clin Oncol 2013；31：4438-44. |
| 135） | Huang D, Ba Y, Xiong J, et al：A multicentre randomised trial comparing weekly paclitaxel＋S-1 with weekly paclitaxel＋5-fluorouracil for patients with advanced gastric cancer. Eur J Cancer 2013；49：2995-3002. |
| 136） | Kunisaki C, Takahashi M, Ono HA, et al：Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer. Anticancer Res 2013；33：697-704. |
| 137） | Li J, Qin S, Xu J, et al：Apatinib for chemotherapy-refractory advanced metastatic gastric cancer：results from a randomized, placebo-controlled, parallel-arm, phase Ⅱ trial. J Clin Oncol 2013；31：3219-25. |
| 138） | Lordick F, Kang YK, Chung HC, et al：Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer（EXPAND）：a randomised, open-label phase 3 trial. Lancet Oncol 2013；14：490-9. |
| 139） | Mochizuki Y, Ohashi N, Kojima H, et al：CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1（CCOG0702）. Cancer Chemother Pharmacol 2013；72：629-35. |
| 140） | Ohtsu A, Ajani JA, Bai YX, et al：Everolimus for previously treated advanced gastric cancer：results of the randomized, double-blind, phase Ⅲ GRANITE-1 study. J Clin Oncol 2013；31：3935-43. |
| 141） | Richards D, Kocs DM, Spira AI, et al：Results of docetaxel plus oxaliplatin（DOCOX）±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma：results of a randomised Phase 2 study. Eur J Cancer 2013；49：2823-31. |
| 142） | Sakai D, Satoh T, Kurokawa Y, et al：A phase Ⅱ trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer：Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203（HERBIS-5）. Jpn J Clin Oncol 2013；43：838-40. |
| 143） | Shirao K, Boku N, Yamada Y, et al：Randomized Phase Ⅲ study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis（JCOG0106）. Jpn J Clin Oncol 2013；43：972-80. |
| 144） | Waddell T, Chau I, Cunningham D, et al：Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer（REAL3）：a randomised, open-label phase 3 trial. Lancet Oncol 2013；14：481-9. |
| 145） | Yamaguchi H, Kitayama J, Ishigami H, et al：A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer 2013；119：3354-8. |
| 146） | Yoshino S, Furuya T, Shimizu R, et al：Combination phase Ⅱ study of weekly paclitaxel and 5’-DFUR for unresectable or recurrent gastric cancer. Anticancer Res 2013；33：2629-33. |
| 147） | Koizumi W, Kim YH, Fujii M, et al：Addition of decetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer：a randomized study（START）. J Cancer Res Clin Oncol 2014；140：319-28. |
| 148） | Furukawa H, Iwanaga T, Nakajima T, et al：Randomized study with mitomycin C＋5-fluorouracil＋cytosine arabinoside（MFC）＋5-fluorouracil, MFC＋tegafur and uracil（UFT）, and MF＋UFT in advanced gastric cancer：interinstitutional differences in a multicenter study in Japan. J Surg Oncol 1995；60：59-64. |
|---|---|
| 149） | Nakajima T, Nashimoto A, Kitamura M, et al：Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer：a randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999；354：273-7. |
| 150） | Mari E, Floriani I, Tinazzi A, et al：Efficacy of adjuvant chemotherapy after curative resection for gastric cancer：a meta-analysis of published randomised trials. A study of the GISCAD（Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente）. Ann Oncol 2000；11：837-43. |
| 151） | Macdonald JS, Smalley SR, Benedetti J, et al：Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001；345：725-30. |
| 152） | Nashimoto A, Nakajima T, Furukawa H, et al：Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer：Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003；21：2282-7. |
| 153） | Cunningham D, Allum WH, Stenning SP, et al：Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006；355：11-20. |
| 154） | Nakajima T, Kinoshita T, Nashimoto A, et al：Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007；94：1468-76. |
| 155） | Sakuramoto S, Sasako M, Yamaguchi T, et al：Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007；357：1810-20. |
| 156） | ”GASTRIC（Global Advanced/Adjuvant Stomach Tumor Research International Collaboration）Group”：Benefit of adjuvant chemotherapy for resectable gastric cancer：a meta-analysis. JAMA 2010；303：1729-37. |
| 157） | Di Costanzo F, Gasperoni S, Manzione L, et al：Adjuvant chemotherapy in completely resected gastric cancer：a randomized phase Ⅲ trial conducted by GOIRC. J Natl Cancer Inst 2008；100：388-98. |
| 158） | Schwartz GK, Winter K, Minsky BD, et al：Randomized phase Ⅱ trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer（RTOG-0114）. J Clin Oncol 2009；27：1956-62. |
| 159） | Kodera Y, Ishiyama A, Yoshikawa T, et al：A feasibility study of postoperative chemotherapy with S-1 and cisplatin（CDDP）for gastric carcinoma（CCOG0703）. Gastric Cancer 2010；13：197-203. |
| 160） | Sasako M, Sakuramoto S, Katai H, et al：Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer. J Clin Oncol 2011；29：4387-93. |
| 161） | Messager M, Lefevre JH, Pichot-Delahaye V, et al：The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma：a multicenter comparative study. Ann Surg 2011；254：684-93. |
| 162） | Takahari D, Hamaguchi T, Yoshimura K, et al：Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol 2011；67：1423-8. |
| 163） | Becker K, Reim D, Novotny A, et al：Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg 2012；256：1002-7. |
| 164） | Lee J, Lim do H, Kim S, et al：Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection：the ARTIST trial. J Clin Oncol 2012；30：268-73. |
| 165） | Bang YJ, Kim YW, Yang HK, et al：Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy（CLASSIC）：a phase 3 open-label, randomised controlled trial. Lancet 2012；379：315-21. |
| 166） | Smalley SR, Benedetti JK, Haller DG, et al：Updated analysis of SWOG-directed intergroup study 0116：a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012；30：2327-33. |
| 167） | Shen L, Shan YS, Hu HM, et al：Management of gastric cancer in Asia：resource-stratified guidelines. Lancet Oncol 2013；12：e535-47. |
| 168） | Piessen G, Messager M, Le Malicot K, et al：Phase Ⅱ/Ⅲ multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas -PRODIGE 19 -FFCD1103 -ADCI002. BMC Cancer 2013；13：281. |
| 169） | Kang YK, Chang HM, Yook JH, et al：Adjuvant chemotherapy for gastric cancer：a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy（AMC0201）. Br J Cancer 2013；108：1245-51. |